Friday, November 14, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Cantor Fitzgerald Analyst Maintains Neutral Rating and 165 Price Target for Alnylam Pharmaceuticals

Elaine Mendonca by Elaine Mendonca
February 15, 2024
in Breaking News
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

On February 15, 2024, Cantor Fitzgerald analyst Olivia Brayer once again expressed a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and upheld a price target of $165 for the company. This affirmation was outlined in a recent report released by Cantor Fitzgerald. The evaluation and price target provided by the analyst hold significant weight, serving as crucial elements for investors to carefully contemplate when contemplating investments in the company’s stock.

ALNY Stock Analysis: Potential Buying Opportunity as Shares Decline and Trade Below Moving Average

On February 15, 2024, Alnylam Pharmaceuticals Inc. (ALNY) experienced a decline in its stock performance, trading near the bottom of its 52-week range and below its 200-day simple moving average. ALNY shares have decreased by $12.34 since the market closed, representing a 7.52% drop. ALNY stock remained unchanged in after-hours trading, closing at $164.15. The fact that ALNY is trading near the bottom of its 52-week range suggests a potential buying opportunity for investors who believe in the long-term prospects of Alnylam Pharmaceuticals. ALNY’s price being below its 200-day simple moving average implies a bearish trend in the stock. The $12.34 decrease in ALNY shares since the market last closed is significant, representing a 7.52% drop. Closing at $164.15, ALNY stock’s performance on February 15, 2024, indicates that it ended the trading day at a relatively low price. However, the stock’s unchanged position in after-hours trading suggests that there may not have been any significant developments or news that could have further impacted its price. Investors should carefully analyze the reasons behind this drop before making any investment decisions. It is crucial to conduct thorough research and analysis before making decisions based solely on stock performance. Investors should consider factors such as the company’s financial health, pipeline of products, competitive landscape, and overall market conditions. Seeking advice from financial professionals or conducting independent research can provide a more comprehensive understanding of ALNY’s investment potential.

ALNY Stock Performance Shows Significant Improvements in Revenue and Profitability

ALNY stock performances on February 15, 2024, showed significant improvements compared to the previous year and quarter, according to data from CNN Money. The company reported a total revenue of $1.04 billion over the past year, representing a 22.88% increase from the previous year. Additionally, the total revenue for the third quarter of 2023 was $750.53 million, indicating a substantial increase of 135.46% compared to the previous quarter.

However, ALNY’s net income figures presented a mixed picture. Over the past year, the company reported a net income of -$1.13 billion, which represented a decrease of 32.64% compared to the previous year. On the other hand, the net income for the third quarter of 2023 was $147.75 million, reflecting a remarkable increase of 153.53% compared to the previous quarter.

Earnings per share (EPS) also exhibited a similar trend. The EPS for the past year was -$9.30, which marked a decrease of 29.11% compared to the previous year. Conversely, the EPS for the third quarter of 2023 was $1.15, indicating a significant increase of 152.02% compared to the previous quarter.

These financial indicators suggest that ALNY has experienced substantial growth in its revenue and profitability over the past year and quarter. The increase in total revenue can be attributed to various factors, such as successful product launches, increased market demand, or expansion into new markets. It is important to note that the company’s net income figures have shown some volatility, with a decrease over the past year but a significant increase in the most recent quarter.

Investors and analysts may interpret these financial results differently, depending on their investment strategies and risk tolerance. While the increase in revenue is generally seen as positive, the decrease in net income over the past year could raise concerns about the company’s profitability. However, the significant improvement in net income and EPS in the most recent quarter indicates a potential turnaround for ALNY.

It is crucial for investors to conduct further research and analysis to gain a comprehensive understanding of ALNY’s financial health and prospects. Factors such as the company’s pipeline of products, competition in the market, and regulatory environment should be considered before making any investment decisions.

Tags: ALNY
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Shake Shacks Promising Future and Strategies for Growth

Healthcare Services Stock Exchange

Revolutionizing Cardiovascular Medicine Cardio Diagnostics Announces Nationwide Rollout of HeartRisk Platform

Finance_ Chart up

The Volatility of NANOX IMAGING Shares Understanding the Factors Behind Price Swings

Recommended

Financing and finances

Analysis of Recent Analyst Ratings and Price Targets for APA

2 years ago

BTIG Analyst Initiates Coverage on flyExclusive with Buy Rating and 9 Price Target

2 years ago

Promising Results of Phase 3 Trial for Cabozantinib and Atezolizumab Combination in Metastatic CastrationResistant Prostate Cancer

2 years ago
Rallybio Stock

Rallybio Shares Navigate Volatility Amid Strategic Pivot

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Political Scrutiny Mounts for UnitedHealth Over Rural Coverage Changes

Opendoor’s Pivot: Can Artificial Intelligence Rescue Its Struggling Business Model?

Adobe’s Innovation Surge Fails to Lift Stock Performance

Lockheed Martin Stock: Defense Titan Mounts Strategic Counteroffensive

Meta’s Spending Spree: Visionary Bet or Investor Nightmare?

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

Trending

FactSet Research Stock
Analysis

Can FactSet Research Shares Sustain Their Recovery Momentum?

by Felix Baarz
November 14, 2025
0

The financial data provider FactSet Research is showing tentative signs of emerging from its prolonged downturn, though...

Wolfspeed Stock

Wolfspeed Shares Surge on Restructuring Milestone

November 14, 2025
Ondas Holdings Stock

Ondas Holdings Soars Following Stellar Quarterly Performance

November 14, 2025
Unitedhealth Stock

Political Scrutiny Mounts for UnitedHealth Over Rural Coverage Changes

November 14, 2025
Opendoor Stock

Opendoor’s Pivot: Can Artificial Intelligence Rescue Its Struggling Business Model?

November 14, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Can FactSet Research Shares Sustain Their Recovery Momentum?
  • Wolfspeed Shares Surge on Restructuring Milestone
  • Ondas Holdings Soars Following Stellar Quarterly Performance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com